Epithalon is one of the most researched longevity peptides. This guide covers the evidence on telomere elongation, dosing protocols, and which biomarkers to monitor.
Quick Summary - Epithalon (Epitalon) is a synthetic tetrapeptide based on epithalamin, isolated from the pineal gland - Primary mechanism: activation of telomerase, the enzyme that rebuilds telomere length - Standard protocol: 5-10 mg daily for 10-20 days, 1-2 cycles per year - No direct serum marker -- track biological age proxies (hs-CRP, HbA1c, IGF-1, telomere length if accessible) - One of the few peptides with direct human longevity research spanning decades
Epithalon (also spelled Epitalon) is a synthetic tetrapeptide -- four amino acids (Ala-Glu-Asp-Gly) -- developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. It is based on epithalamin, a naturally occurring polypeptide extract from bovine pineal glands.
The research history of epithalon spans more than three decades and includes human studies -- unusual in the peptide space where most evidence is animal-derived. The most notable studies examined all-cause mortality and cancer incidence in elderly populations over 12-18 year follow-up periods, showing meaningful improvements in survival in epithalon-treated groups versus controls.
The primary proposed mechanism -- telomerase activation -- places epithalon at the center of one of the most active areas of longevity research.
Telomeres are protective caps at the ends of chromosomes. With each cell division, telomeres shorten slightly. When telomeres become critically short, cells enter senescence (functional shutdown) or apoptosis (cell death). Telomere shortening is considered one of the primary hallmarks of aging.
Telomerase is the enzyme that rebuilds telomere length. In most adult cells, telomerase is nearly inactive -- which is why telomeres shorten with age. Certain cells that need to divide continuously (immune cells, stem cells) maintain higher telomerase activity.
Epithalon appears to activate telomerase expression in cultured cells and in animal models. In human fibroblast studies, epithalon treatment increased telomere length and extended cell lifespan in culture. Whether this translates to meaningful telomere length restoration in vivo at therapeutic doses remains an active area of research.
The Khavinson protocol used in the Russian longevity research:
More recently, some longevity practitioners have explored lower-dose continuous protocols (2-3 mg every other day or 3x weekly), though this deviates from the original research protocol.
Epithalon arrived on the RFK Jr. reclassification list, expected to return to legal compounding status through licensed pharmacies.
Epithalon does not have a direct serum marker that reflects its activity. Instead, track biological age proxies -- markers associated with cellular aging and longevity:
hs-CRP: Inflammaging (chronic low-grade inflammation associated with aging) drives much of the age-related decline epithalon targets. Track hs-CRP before and after a cycle. Target under 1.0 mg/L.
HbA1c and fasting glucose: Metabolic health is a primary determinant of biological aging rate. Track at baseline and at 3-6 month intervals.
IGF-1: GH axis function declines with age and is one of the primary longevity biomarkers. Track alongside epithalon if also running GH peptides.
Telomere length testing: If you want to directly track epithalon primary mechanism, telomere length testing is available through companies like TeloYears or Life Length. These tests measure average telomere length in leukocytes. Expensive (typically $200-400) and highly variable, but the only direct measure of what epithalon is theoretically affecting.
CBC with differential: Epithalon has immune-modulating effects. Tracking white blood cell populations (particularly NK cells and T-cell subsets) gives indirect signal on immune function changes.
Is epithalon the same as epitalon?
Yes -- two spellings of the same compound. Epithalon is the more common scientific spelling; epitalon is used in some commercial contexts.
How long before effects are noticeable?
Most users report subjective improvements in sleep quality within the first cycle. Objective changes in longevity biomarkers are measured over months to years, not days.
Can epithalon be stacked with other peptides?
Yes -- epithalon is commonly stacked with BPC-157, GHK-Cu, and MOTS-c in comprehensive longevity protocols. No significant interactions are known.
Is there cancer risk from telomerase activation?
This is the primary theoretical concern about telomerase activation -- cancer cells also use telomerase to achieve immortality. The available human research on epithalon shows reduced cancer incidence, not increased, but this remains a legitimate consideration to discuss with a physician, particularly for users with personal or family cancer history.
What does the human longevity research actually show?
The 12-18 year follow-up studies by Khavinson showed approximately 1.6-fold reduction in mortality rate and reduced cancer incidence in elderly subjects treated with epithalamin (the natural precursor) versus controls. Epithalon is the synthetic tetrapeptide derived from this research. Direct replication of these findings by independent researchers is limited but ongoing.
The information in this article is for educational purposes only. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any peptide protocol.
Written by Ryan -- Founder, MyProtocolStack. Last Updated: April 2026.
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers -- not generic charts.
Start Free →